Compare J B Hunt Transport Services Inc (JBHT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Neurocrine Biosciences Inc — how do they compare? J B Hunt Transport Services Inc trades at $229 (market cap $21.45B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: J B Hunt Transport Services Inc is the larger of the two by market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 45 Days and Neurocrine Biosciences Inc for 23 Days on average.
| JBHT | NBIX | |
|---|---|---|
Market Cap | $21.45B | $14.36B |
Volume | 1,028,680 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $298.41 | $185.50 |
52-Week Low | $137.09 | $123.10 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | $22.59B | $14.37B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $222.64, down 1.46% on the day, amid a bearish technical signal and ongoing securities class action investigations. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected October 15, 2026. Fundamentals show a P/E of 31.67, net income margin of 5.31%, and strong cash flow from operations of $1.68 billion in 2025. Analyst consensus remains bullish with a $289.40 price target, though rising costs and legal scrutiny present headwinds.
The outlook is mixed; strong freight demand and earnings beats support upside potential, but near-term pressure from fuel costs and legal overhangs may limit gains. The stock offers value if operational efficiency improves, yet investors face risks from volatile diesel prices and potential litigation outcomes. The upcoming Q3 earnings will be critical for confirming the company's ability to navigate cost pressures.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
